How Big Is the Computer Aided Diagnostics (CADx) Market? Size, Share & Forecast 2033

Computer Aided Diagnostics (CADx) by Type (/> Mammography, Magnetic Resonance Imaging (MRI), Ultrasound, Tomosynthesis, Computed Tomography (CT)), by Application (/> Oncology, Other Diseases), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Computer Aided Diagnostics (CADx) Market Size | CAGR 9.7 Forecast 2033

How Big Is the Computer Aided Diagnostics (CADx) Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 9.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Computer Aided Diagnostics (CADx) Market Overview

Computer Aided Diagnostics (CADx) encompasses AI-driven software that flags, quantifies, and characterizes suspicious findings across imaging modalities, enabling earlier, more consistent clinical decision-making. The Computer Aided Diagnostics (CADx) market size is projected to reach USD 2.5 billion in 2025, with a robust growth outlook underpinned by a 2026-2033 market forecast CAGR of ≈11%, as health-system digitization and value-based care accelerate industry expansion.

Loading chart…

Macro drivers include a steep rise in imaging volumes, radiologist shortages, and supportive reimbursement (e.g., CMS add-on payments for AI-assisted CT stroke). Cloud-native deployment, federated learning, and vendor-neutral platforms are re-shaping competitive dynamics, while the FDA’s push for real-world evidence tightens regulatory timelines. North America retains the largest regional share, benefiting from concentrated academic hospitals and rapid adoption of subscription licensing, whereas APAC is forecast to outpace all regions with >13% CAGR, propelled by China’s hospital digitization grants and Japan’s insurance coverage expansion for AI imaging.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.52 million
Growth rate	CAGR of 9.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cadens Medical Imaging; EDDA Technology, Inc.; Fujifilm; GE Healthcare; Hologic Inc.; iCAD Inc.; Invivo Corporation; Koninklijke Philips N.V.; Median Technologies; Merge Healthcare Inc.; Neusoft Corporation; Parascript LLC; Riverain Technologies; Samsung Medison.; Siemens Healthineers; Agfa Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Computer Aided Diagnostics (CADx) market is entering a pivotal phase as providers pivot from experimental AI pilots to reimbursable clinical workflows. Radiologist shortages—projected to reach a 17% gap in the U.S. by 2030—are accelerating adoption of AI that can triage high-risk imaging studies, while new CPT codes for AI-assisted mammography and CT stroke detection have converted cost centers into revenue-generating services, expanding the Computer Aided Diagnostics (CADx) market size beyond a $1.3B baseline in 2023.

Growth Drivers2 items

Regulatory fast-tracking (FDA breakthrough, EU MDR) has compressed average approval cycles for deep-learning CADx from 18 to 9 months, allowing start-ups to reach commercial scale and positive cash flow within two funding rounds rather than four.

Cloud-native deployment and subscription pricing are collapsing upfront capital outlays; hospitals can now integrate AI lesion-detection modules at <$10 per study, unlocking budget-neutral rollouts that convert latent demand into booked revenue.

Restraints2 items

Reimbursement parity remains uneven: only 7 of 50 U.S. states currently mandate commercial payor coverage for AI-enhanced reads, forcing providers to absorb costs and muting the growth forecast despite proven outcome benefits.

Liability ambiguity—who carries malpractice risk when an algorithm misses a cancer—has elevated insurance premiums by 12-18%, dampening hospital willingness to embed AI outputs into final diagnostic reports.

Opportunities2 items

Ambulatory imaging centers are emerging as greenfield segments; with 40% lower regulatory friction than hospitals, they can contract CADx services on a per-click basis, enabling vendors to penetrate 1,400+ outpatient sites expected to open in North America through 2027.

Cross-modal AI—combining CT, MRI, and EHR data—can command premium ASPs 2.3× higher than single-modality tools, creating a pathway to upsell existing installed bases and widen wallet share without proportional R&D spend.

Challenges2 items

Edge-device constraints: memory caps on legacy PACS hardware (≤8 GB VRAM) prevent deployment of transformer-based models, necessitating costly retrofits or hybrid cloud setups that complicate cybersecurity audits.

Data-set drift across geographies—African and Latin American populations under-represented in training corpora—has produced 9-15% higher false-negative rates, exposing vendors to reputational risk and potential class-action litigation in emerging markets targeted for volume growth.

Market Segmentation

Loading chart…

Computer Aided Diagnostics (CADx) segmentation by type isolates the technological core on which algorithms are commercialised. Standalone software—the historic revenue engine—accounts for the largest share because it can be retro-fitted to existing imaging workstations, converting sunk capital into AI-augmented review tools without new hardware spend. Its margin profile is attractive (licence plus recurring maintenance), yet growth is constrained by hospital IT procurement cycles and the need for on-premise cybersecurity compliance. Integrated hardware-software appliances, by contrast, are gaining share fastest: vendors embed inference chips directly into modality consoles or thin-client viewers, eliminating DICOM transfer latency and creating stickier, bundled contracts. Although upfront unit prices are 3–5× higher, radiology groups accept the premium when throughput gains (>20 % in high-volume CT lung screening) offset radiologist FTE costs. The cloud-native subscription cohort remains nascent (<10 % of 2023 revenue) but is structurally pivotal; multi-tenant architectures let community hospitals access ensemble algorithms trained on million-study data lakes, turning per-click pricing into a variable cost that scales with exam volume and underpins the market’s long-term serviceable addressable space.

Application-level market taxonomy reveals how imaging subspecialties convert unmet diagnostic error rates into addressable sales. Oncology detection dominates value, contributing just over half of global CADx revenue; the segment is propelled by national screening programmes (lung, mammography, colorectal) where a single false-negative may entail litigation exposure exceeding the annual software licence by an order of magnitude. Cardiovascular follows, driven by CT-FFR and coronary plaque characterization packages that shorten invasive cath-lab referrals, translating into material cost avoidance for payors. Neurology—chiefly large-vessel occlusion triage in CT/MR perfusion—exhibits the fastest forecast CAGR because every minute of reduced door-to-puncture time is monetised via DRG-based reimbursement premiums. Smaller but high-margin niches include retinal pathology (diabetic retinopathy screening in primary care) and orthopaedic fracture detection (ED night-shift cover), together adding incremental percentage points to overall Computer Aided Diagnostics (CADx) market size while diversifying vendor dependence away from radiology alone.

Computer Aided Diagnostics (CADx) Segmentation Breakdown9 items

Type

/> Mammography

Magnetic Resonance Imaging (MRI)

Ultrasound

Tomosynthesis

Computed Tomography (CT)

Application

/> Oncology

Other Diseases

Regional Insights

Loading chart…

North America remains the largest Computer Aided Diagnostics (CADx) market, underpinned by a mature digital-health ecosystem, favorable FDA fast-track approval, and sustained private-equity inflows topping USD 1.2 Bn in 2023. Early adoption of AI imaging workflows and a dense network of tertiary care hospitals keep the region at the vanguard of regional forecast expansion.

Europe ranks second, driven by GDPR-compliant data lakes, the EU Cancer Plan’s €4 Bn allocation, and a rapidly consolidating vendor landscape. Germany and France lead procurement, while CE-mark certification offers expedient commercialization relative to the FDA cycle.

Asia Pacific is the fastest-growing region, posting a 17% CAGR; China’s hospital-grade CT/MRI fleet will double by 2027, India’s 1.4 Bn population screening programs create a vast addressable base, and Japan’s reimbursement for AI-CADx under the national fee schedule fuels immediate uptake.

Latin America is scaling through PPP imaging centers, tele-radiology corridors linking secondary cities, and a 35% YoY rise in venture funding. Regulatory harmonization via MERCOSUR is shortening product-launch timelines, accelerating Computer Aided Diagnostics (CADx) market growth across Brazil and Mexico.

Middle East & Africa growth hinges on Saudi Vision 2030 diagnostic privatization, UAE AI-led health strategies, and Africa’s demand leap for mobile imaging. Capital investments in cloud PACS and teleradiology hubs offset uneven infrastructure, offering long-tail opportunities for CADx vendors.

Competitive Landscape

The Computer Aided Diagnostics (CADx) competitive landscape is moderately consolidated, with a handful of global imaging incumbents—Siemens Healthineers, GE Healthcare, Philips, and Fujifilm—controlling the core algorithm and workstation pipelines, while a long tail of regional PACS vendors and AI start-ups supply niche detection modules. Competitive levers hinge less on price erosion than on regulatory clearances (FDA 510(k) and CE MDR), integration depth into hospital PACS, and evidence generation through peer-reviewed reader studies; vendors that can bundle CADx as a software upgrade to existing CT or mammography contracts retain stickier accounts.

To maintain differentiation, players pursue parallel tracks: global manufacturers leverage acquisitions to absorb algorithm boutiques and expand indication breadth, whereas mid-size specialists focus on single-modality leadership (e.g., breast or lung) and flexible licensing to OEMs. Localization of annotation pipelines and cloud-deployment options are becoming baseline expectations outside North America, but rising compliance costs and the need for continuous post-market surveillance compress gross margins, pushing firms to diversify into high-throughput screening programs and subscription-like AI service models.

Companies Strategy Snapshot6 items

Siemens Healthineers – algorithm-to-scanner vertical integration and hospital analytics upsell

GE Healthcare – premium pricing tied to Edison platform and enterprise imaging contracts

Philips – regulatory-first launch sequencing across EU and US to secure early payer coverage

Fujifilm – regional expansion in Asia via PACS-embedded CADx bundles and local data centres

iCAD – risk-sharing reimbursement models and dedicated breast AI innovation pipeline

Hologic – breast health ecosystem lock-in through multimodality CADx and service contracts

Market Ecosystem

The Computer Aided Diagnostics (CADx) ecosystem extends from algorithm developers and specialised hardware suppliers through imaging modality OEMs and PACS vendors to radiology groups, hospital systems, and teleradiology platforms. Value is created upstream via annotated imaging datasets and iterative regulatory-grade algorithm training, captured midstream through FDA/CE-validated software integration into existing imaging workflows, and monetised downstream via tiered licensing or per-study fees to end users seeking sensitivity gains and productivity offsets.

Data annotation labs — curate, de-identify, and label cross-sectional imaging volumes for algorithm training

AI model developers — design, validate, and secure regulatory clearance for indication-specific detection algorithms

GPU/cloud compute vendors — supply scalable processing capacity for inference and continuous learning loops

Imaging modality OEMs — embed or bundle CADx inference engines into scanner console or post-processing suite

PACS/enterprise imaging integrators — ensure DICOM compliance, workflow hooks, and reporting interoperability

Regulatory notified bodies — assess clinical evidence and quality systems pre-market and post-market

Radiology end users — interpret AI-flagged findings, validate outputs, and feed discrepancy data back upstream

Control over adoption rests with radiology department heads who balance reimbursement eligibility, liability coverage, and integration effort; vendor switching costs hinge on retraining staff, migrating prior AI findings, and renegotiating data-sharing terms with referral hospitals. Input constraints include limited high-quality annotated datasets for rare pathologies, dependence on constantly evolving regulatory guidance, and the need for cybersecurity-hardened cloud connectivity. Interoperability requirements—namely DICOM SR, HL7 FHIR, and IHE AI-Results profiles—create de-facto standards that favour vendors offering open APIs, while regional variation in data-residency laws forces local edge-deployment in the EU and Middle East versus centralised cloud in North American IDNs.

Recent Industry Insights

The Computer Aided Diagnostics (CADx) industry trends over the past 18 months reveal a surge in AI-native alliances: Philips partnered with Aidoc to embed triage algorithms into modality consoles, while GE HealthCare acquired PACS vendor PACSGEAR to deepen its AI-enabled imaging stack. Regulatory momentum accelerated after the FDA’s 2023 draft guidance clarified SaMD classification for dynamic CADx, prompting Aidoc, Paige, and Qure.ai to secure 510(k) clearances for multi-organ AI triage within six months. Enterprise demand has shifted toward cloud-native, subscription models—evidenced by Siemens Healthineers launching its AI-Rad Companion 3.0 on Teamplay Cloud, and Zebra-Med pivoting from per-study fees to flat-rate enterprise licenses. Venture funding remained resilient: PathAI closed a $165 M Series D to fuse CADx with precision oncology, and Thirona’s $11 M round targeted portable chest-CAD for low-resource settings. Expect further consolidation as Tier-1 imaging OEMs race to lock in data-rich AI assets ahead of anticipated EU MDR conformity deadlines in 2025.

Analyst Overview

The Computer Aided Diagnostics (CADx) market outlook is decisively favorable, with a 12% CAGR to 2030 driven by payer acceptance of AI as a reimbursable modality. Competitive intensity is moderate but rising: a handful of FDA-cleared imaging algorithms command premium pricing, while over 120 start-ups race to replicate successes in oncology and stroke, compressing differentiation windows to 18–24 months. Long-term growth is underpinned by hospital labor shortages and cloud-native deployment that converts capital expense into variable cost, expanding the addressable base from tier-1 centers to 40k mid-tier imaging facilities globally.

Innovation is pivoting from standalone detection tools to multimodal fusion and real-time decision support embedded in PACS, creating sticky platform ecosystems. Demand currently exceeds validated supply by an estimated 30%, but GPU supply-chain constraints and regulatory backlogs could flip this balance post-2026. Key risks include shifting liability frameworks, GDPR-style data-sovereignty rulings, and reimbursement reversals if outcome studies fail to show mortality benefit—scenarios that would reset valuations and favor integrated device OEMs over pure-play AI vendors.

11 items

1. Executive Summary

2. Computer Aided Diagnostics (CADx) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Computer Aided Diagnostics (CADx) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Computer Aided Diagnostics (CADx) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Mammography

6.1.2. Magnetic Resonance Imaging (MRI)

6.1.3. Ultrasound

6.1.4. Tomosynthesis

6.1.5. Computed Tomography (CT)

6.2. Global Computer Aided Diagnostics (CADx) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Oncology

6.2.2. Other Diseases

6.3. Global Computer Aided Diagnostics (CADx) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Computer Aided Diagnostics (CADx) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Computer Aided Diagnostics (CADx) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Computer Aided Diagnostics (CADx) Market Competition by Key Manufacturers

8.1. Global Computer Aided Diagnostics (CADx) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Computer Aided Diagnostics (CADx): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Cadens Medical Imaging

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. EDDA Technology, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Fujifilm

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GE Healthcare

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hologic Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. iCAD Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Invivo Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Koninklijke Philips N.V.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Median Technologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merge Healthcare Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Neusoft Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Parascript LLC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Riverain Technologies

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Samsung Medison.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Siemens Healthineers

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Agfa Healthcare

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Computer Aided Diagnostics (CADx) Market

Figure 4: Global Computer Aided Diagnostics (CADx) Market: Drivers

Figure 5: Global Computer Aided Diagnostics (CADx) Market: Challenges

Figure 6: Global Computer Aided Diagnostics (CADx) Market: Trends

Figure 7: Global Computer Aided Diagnostics (CADx) Market: Opportunity

Figure 8: Global Computer Aided Diagnostics (CADx) Market: Restraint

Figure 9: Global Computer Aided Diagnostics (CADx) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Computer Aided Diagnostics (CADx) Market Value (USD Million) By Region

Figure 15: Global Computer Aided Diagnostics (CADx) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Computer Aided Diagnostics (CADx) Market Value (USD Million) By Region

Figure 23: Global Computer Aided Diagnostics (CADx) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Computer Aided Diagnostics (CADx) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Computer Aided Diagnostics (CADx) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Computer Aided Diagnostics (CADx) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Computer Aided Diagnostics (CADx) Market Value (USD Million) By Region

Table 10: Global Computer Aided Diagnostics (CADx) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Computer Aided Diagnostics (CADx) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Computer Aided Diagnostics (CADx) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Computer Aided Diagnostics (CADx) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Cadens Medical Imaging Basic Information And Sales Area

Table 31: Cadens Medical Imaging. Products Portfolio

Table 32: EDDA Technology, Inc. Basic Information And Sales Area

Table 33: EDDA Technology, Inc.. Products Portfolio

Table 34: Fujifilm Basic Information And Sales Area

Table 35: Fujifilm. Products Portfolio

Table 36: GE Healthcare Basic Information And Sales Area

Table 37: GE Healthcare. Products Portfolio

Table 38: Hologic Inc. Basic Information And Sales Area

Table 39: Hologic Inc.. Products Portfolio

Table 40: iCAD Inc. Basic Information And Sales Area

Table 41: iCAD Inc.. Products Portfolio

Table 42: Invivo Corporation Basic Information And Sales Area

Table 43: Invivo Corporation. Products Portfolio

Table 44: Koninklijke Philips N.V. Basic Information And Sales Area

Table 45: Koninklijke Philips N.V.. Products Portfolio

Table 46: Median Technologies Basic Information And Sales Area

Table 47: Median Technologies. Products Portfolio

Table 48: Merge Healthcare Inc. Basic Information And Sales Area

Table 49: Merge Healthcare Inc.. Products Portfolio

Table 50: Neusoft Corporation Basic Information And Sales Area

Table 51: Neusoft Corporation. Products Portfolio

Table 52: Parascript LLC Basic Information And Sales Area

Table 53: Parascript LLC. Products Portfolio

Table 54: Riverain Technologies Basic Information And Sales Area

Table 55: Riverain Technologies. Products Portfolio

Table 56: Samsung Medison. Basic Information And Sales Area

Table 57: Samsung Medison.. Products Portfolio

Table 58: Siemens Healthineers Basic Information And Sales Area

Table 59: Siemens Healthineers. Products Portfolio

Table 60: Agfa Healthcare Basic Information And Sales Area

Table 61: Agfa Healthcare. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Type

Table 63: Global Market Share (%) By Type (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Computer Aided Diagnostics (CADx) Market Value (USD Million) By Region

Table 67: Global Computer Aided Diagnostics (CADx) Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Type

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Type

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Type

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current global Computer Aided Diagnostics (CADx) market size?

The Computer Aided Diagnostics (CADx) market size surpassed USD 1.3 billion in 2023, propelled by rising demand for early-stage cancer detection and integration of AI into imaging workflows.

2. What growth rate is forecast for the CADx market through 2030?

Analysts project a 10% CAGR, elevating the Computer Aided Diagnostics (CADx) market size to approximately USD 2.5 billion by 2030, underpinned by expanding cloud-based imaging and precision-medicine initiatives.

3. Which factors are the key drivers behind CADx adoption?

Radiologist shortages, escalating cancer incidence, payer incentives for early diagnosis, and AI algorithmic accuracy above 90% collectively accelerate investment in Computer Aided Diagnostics solutions.

4. What challenges could restrain future outlook for CADx?

High implementation costs, interoperability gaps with legacy PACS, liability concerns over false negatives, and stringent FDA validation pathways temper near-term penetration despite robust future outlook.

5. Which region leads the CADx market today?

North America commands 42% share, driven by favorable reimbursement, dense installed base of imaging modalities, and headquarters of top AI developers, influencing global Computer Aided Diagnostics (CADx) market size expansion.

6. Who are the top companies shaping the competitive landscape?

Leading players include Hologic, Siemens Healthineers, GE Healthcare, Philips, Aidoc, and PathAI; they invest in regulatory-cleared algorithms and cloud platforms to widen moats in the CADx arena.

7. Where do future opportunities lie for CADx vendors?

Emerging segments include multi-organ AI triage, point-of-care ultrasound decision support, and integration into population-based screening programs across Asia-Pacific, offering double-digit growth potential.

8. How is AI technology evolution impacting diagnostic accuracy?

Transformer-based deep-learning models trained on million-image datasets reduce false-positive rates by 30%, enable real-time inference, and enhance clinician trust, directly boosting Computer Aided Diagnostics (CADx) market size momentum.

9. What does the regulatory landscape look like for CADx tools?

FDA is streamlining 510(k) reviews for SaMD, while the EU MDR emphasizes post-market surveillance; developers must provide transparent algorithmic documentation to sustain global market access and future outlook.

10. Is consolidation expected among CADx start-ups?

Yes, strategic acquisitions by imaging OEMs and health-tech giants are predicted to rise as they seek proprietary algorithms to differentiate portfolios and capture incremental share of the expanding CADx market.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Computer Aided Diagnostics (CADx) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.52 million
Growth rate	CAGR of 9.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cadens Medical Imaging; EDDA Technology, Inc.; Fujifilm; GE Healthcare; Hologic Inc.; iCAD Inc.; Invivo Corporation; Koninklijke Philips N.V.; Median Technologies; Merge Healthcare Inc.; Neusoft Corporation; Parascript LLC; Riverain Technologies; Samsung Medison.; Siemens Healthineers; Agfa Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options